Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Novel 7H-[1,2,4]Triazolo[3,4-b]thiadiazine-based Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Directed toward Treatment of Cystic Fibrosis.
Rab A, Yang X, Tracy WF, Hong JS, Joshi D, Manfredi C, Ponnaluri SS, Kolykhalov AA, Qui M, Fu H, Du Y, Davies HML, Sorscher EJ. Rab A, et al. Among authors: qui m. ACS Med Chem Lett. 2023 Sep 20;14(10):1338-1343. doi: 10.1021/acsmedchemlett.3c00155. eCollection 2023 Oct 12. ACS Med Chem Lett. 2023. PMID: 37849531 Free PMC article.
TMPRSS2 and SARS-CoV-2 SPIKE interaction assay for uHTS.
Cicka D, Niu Q, Qui M, Qian K, Miller E, Fan D, Mo X, Ivanov AA, Sarafianos SG, Du Y, Fu H. Cicka D, et al. Among authors: qui m. J Mol Cell Biol. 2023 Aug 3;15(3):mjad017. doi: 10.1093/jmcb/mjad017. J Mol Cell Biol. 2023. PMID: 36921991 Free PMC article.
Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
Kelvin JM, Chimenti ML, Zhang DY, Williams EK, Moore SG, Humber GM, Baxter TA, Birnbaum LA, Qui M, Zecca H, Thapa A, Jain J, Jui NT, Wang X, Fu H, Du Y, Kemp ML, Lam WA, Graham DK, DeRyckere D, Dreaden EC. Kelvin JM, et al. Among authors: qui m. J Control Release. 2023 Sep;361:470-482. doi: 10.1016/j.jconrel.2023.07.045. Epub 2023 Aug 14. J Control Release. 2023. PMID: 37543290
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML.
Kelvin JM, Jain J, Thapa A, Qui M, Birnbaum LA, Moore SG, Zecca H, Summers RJ, Costanza E, Uricoli B, Wang X, Jui NT, Fu H, Du Y, DeRyckere D, Graham DK, Dreaden EC. Kelvin JM, et al. Among authors: qui m. bioRxiv [Preprint]. 2023 Mar 15:2023.03.13.531236. doi: 10.1101/2023.03.13.531236. bioRxiv. 2023. PMID: 36993676 Free PMC article. Updated. Preprint.
58 results